AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
LeukemiaLeukemia, Myeloid, AcuteAcute DiseaseCytarabineDaunorubicinChromosomes, Human, 4-5Leukemia, LymphoidLeukemia, Monocytic, AcutePreleukemiaLeukemia, Lymphocytic, Chronic, B-CellLeukemia, Radiation-InducedBone MarrowThioguanineChromosomes, Human, 6-12 and XKaryotypingChromosomes, Human, 16-18Chromosomes, Human, 21-22 and YChromosomes, Human, 1-3Chromosome AberrationsPrecursor Cell Lymphoblastic Leukemia-LymphomaQuinacrine MustardChromosome DisordersRemission InductionAminoacridinesMechlorethamineVincristineLeukemia, MyeloidBone Marrow TransplantationTranslocation, GeneticAntineoplastic Combined Chemotherapy ProtocolsProcarbazineMyelodysplastic SyndromesChromosome BandingPrednisonePrognosisColony-Forming Units AssayRecurrenceDrug Administration ScheduleHematopoietic Stem CellsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHodgkin DiseaseClone CellsLeukemia, B-CellLeukemia, ExperimentalLeukemia, T-CellTime FactorsAntineoplastic AgentsLeukemic InfiltrationLeukemia, Biphenotypic, AcuteAsparaginasePrecursor B-Cell Lymphoblastic Leukemia-LymphomaGene Expression Regulation, LeukemicLeukemia Virus, MurineVidarabineB-LymphocytesLeukemia, Hairy CellMethotrexateLeukemia-Lymphoma, Adult T-CellRemission, SpontaneousLymphocytes, Null6-MercaptopurineImmunoglobulin Heavy ChainsLymphomaBurkitt LymphomaReceptors, Antigen, B-CellZAP-70 Protein-Tyrosine KinaseMoloney murine leukemia virusChlorambucilPhiladelphia ChromosomeLeukemia L1210DNA, NeoplasmFusion Proteins, bcr-ablRosette FormationTumor Cells, CulturedLeukemia Virus, BovineLeukemia Virus, FelineAnisocoriaLymphocytesCladribineAntigens, NeoplasmT-LymphocytesCorneal PerforationLeukemia P388Neoplasm ProteinsAntibodies, MonoclonalDrug Resistance, NeoplasmAntigens, CD5Flow CytometryDNA NucleotidylexotransferaseCyclophosphamideAntigens, CD38Leukemia, Prolymphocytic, T-CellBlast CrisisBase SequenceCombined Modality TherapyMyeloid-Lymphoid Leukemia ProteinTreatment OutcomeMutationImmunoglobulin Variable RegionNeprilysin
Myeloid leukemiaLymphoblastic leukemiaLymphoid leukemia1980Pediatric patientsSubtypeDiagnosisMalignanciesChildhoodSurvivalClonalChemotherapyCasesAnalysisStudiesTreatmentTypesGenerallyProductsPreviouslyMyelogenous leukemiaOccupationally exposedCancersChronic myelomonMortalityIncidenceChildhood leukemiaTreated with rituximabDoxorubicinAdultsChemotherapy in patientsSecondary1990AdultDosageIndicationsExposureElderlyBreast cancerTypeAssociationBloodTherapyGrowthAgentsCancer patientsSupportCommonTreatmentEvidence
Myeloid leukemia8
Lymphoblastic leukemia2
  • Unravelling an HLA-DR association in childhood acute lymphoblastic leukemia. (bdbiosciences.com)
  • It is concluded a prevalence of leukemia in pediatric patients, with a predominance of the subtype Acute Lymphoblastic Leukemia (ALL). (sld.cu)
Lymphoid leukemia2
  • [ 1 , 2 , 3 ] Owing to the variety of hematologic malignancies or proliferative disorders that may be associated with leukemia cutis, terms such as myeloid or lymphoid leukemia cutis have been used to further classify the leukemic cells. (medscape.com)
  • A15 - Torlontano G, Geraci L, Lombardo M, Iacone A, FIORITONI G, Di Marzio A, D'Arcangelo L: Treatment of acute non - lymphoid leukemia with vincristine adryamicine and cytosine arabinoside (AVA).Proc.of 2nd Internat. (giuseppefioritoni.it)
19802
  • The patients were eligible for inclusion in the study if they were less than 10 years old at the time of diagnosis (1980 to 1984), and if the biological mother was available for interview. (cdc.gov)
  • 1980. Acute toxicity tests: Unleaded motor gasoline. (cdc.gov)
Pediatric patients1
  • Washington，D.C.），2005，Abst L-579标题 PK/PD analysis of Tebipenem Pivoxil (ME1211),a Novel Oral Carbapenem Antibiotic,in otolaryngological infections,a phase II clinical trial； 3、PK-PD analysis of tebipenem pivoxil in clinical trials for pediatric patients. (yaozh.com)
Subtype2
  • The subtype of leukemia is determined by the hematopoietic lineage of neoplastic cells and the stage at which maturational arrest occurs. (medscape.com)
  • Some antecedents are specific to a leukemia subtype, such as the association of acute T-cell leukemia-lymphoma (ATL) with human T-lymphotropic virus type I (HTLV-1). (medscape.com)
Diagnosis4
  • The dermatologist is often instrumental in the diagnosis of leukemia cutis. (medscape.com)
  • Accurate diagnosis has tremendous prognostic significance and may establish a diagnosis in cases in which leukemia cutis is the harbinger of a systemic leukemic process. (medscape.com)
  • A diagnosis of leukemia cutis in the setting of acute leukemia generally portends a poor prognosis and strongly correlates with additional sites of extramedullary involvement. (medscape.com)
  • Immunological detection of blast cell subpopulations in acute myeloblastic leukemia at diagnosis: implications for minimal residual disease studies. (bdbiosciences.com)
Malignancies1
Childhood1
Survival2
  • The 2-year and 5-year survival rates were 72% and 55% in patients with LD and 43% and 0% in patients with extensive disease, respectively. (the-medical-dictionary.com)
  • In patients with limited disease (LD), the CR rate is 16 to 18%, with a median survival of 11.7 to 12.4 months. (the-medical-dictionary.com)
Clonal1
  • Leukemia is a group of clonal diseases derived from a single cell with a genetic alteration in bone marrow or peripheral lymphoid tissue, and each type is determined by the specificity of the source cell. (sld.cu)
Chemotherapy1
  • Conclusion: Double-cycle, high-dose ICE therapy followed by PBSCT is tolerable and feasible even after conventional chemotherapy or chemoradiotherapy in patients with SCLC. (the-medical-dictionary.com)
Cases4
  • Cases of acute leukemia were identified from the population based cancer registry, the Los Angeles County Cancer Surveillance Program. (cdc.gov)
  • There were 107 cases with acute lymphocytic leukemia (ALL) and 16 cases with acute nonlymphocytic leukemia (ANLL). (cdc.gov)
  • In rare cases, leukemia cutis may be the first manifestation of systemic disease. (medscape.com)
  • The objective of this research was to synthesize studies that characterize the clinical and epidemiological profile of patients with leukemia, the types of treatments used, duration and outcomes for the cases. (sld.cu)
Analysis1
  • The analysis showed a statistically significant risk of leukemia for children whose fathers had been occupationally exposed, after the birth of the children and mainly during the first year of life, to chlorinated solvent s, spray paints, dyes or pigments, methyl-ethyl- ketone (78933) and cutting oil. (cdc.gov)
Studies2
  • The authors state that their results are consistent with those of animal studies which show that carcinogenic compounds are more likely to induce leukemia in mice exposed shortly after birth than in those exposed in-utero or as adults. (cdc.gov)
  • A9 - Torlontano G, FIORITONI G, Pontano O, Iacone A, Bonanni G: Normal granulocyte transfusion therapy in the management of acute leukemias.Current Studies on Standardization Problems in Clinical Patholology, Haematology and Radiotherapy in Hodgkin's Disease.Eds: G. Astaldi, C. Biagini. (giuseppefioritoni.it)
Treatment2
  • [ 1 ] This can significantly alter the treatment regimen for a patient. (medscape.com)
  • Chronic leukemia showed higher treatment duration. (sld.cu)
Types2
Generally1
  • Patients are generally advised to call their doctor in case of fever, symptoms of infection or painful injection sites, as these may progress severely without adequate medical attention. (the-medical-dictionary.com)
Products1
  • A case/control study was made of the effect of parents' exposure to chemicals and other products on the incidence of leukemia in their children. (cdc.gov)
Previously2
  • Leukemia cutis usually occurs in the setting of a previously diagnosed systemic leukemia or lymphoproliferative disorder/myelodysplastic syndrome. (medscape.com)
  • Leukemia cutis can also be a manifestation of a relapse of previously treated systemic leukemia. (medscape.com)
Myelogenous leukemia1
  • Within this population, acute lymphocytic leukemia (ALL) occurs approximately five times more frequently than acute myelogenous leukemia (AML) and accounts for approximately 78% of all childhood leukemia diagnoses. (nih.gov)
Occupationally exposed2
  • The analysis showed a statistically significant risk of leukemia for children whose fathers had been occupationally exposed, after the birth of the children and mainly during the first year of life, to chlorinated solvent s, spray paints, dyes or pigments, methyl-ethyl- ketone (78933) and cutting oil. (cdc.gov)
  • The strongest evidence for health effects comes from associations observed in human populations with two forms of cancer: childhood leukemia and chronic lymphocytic leukemia in occupationally exposed adults. (nih.gov)
Cancers4
  • Doxorubicin, epirubicin, idarubicin and valrubicin are structurally related cytotoxic antineoplastic antibiotics used in the therapy of several forms of lymphoma, leukemia, sarcoma and solid organ cancers. (nih.gov)
  • Although overall incidence is rare, leukemia is the most common type of childhood cancer, accounting for 30% of all cancers diagnosed in children younger than 15 years ( Linet 1999 ). (nih.gov)
  • [ 2 ] Recent data have suggested that as many as 56.0% of patients with gastrointestinal cancers have clinically significant weight loss at first referral. (medscape.com)
  • Stomach cancer, representing 31% of the cancers in this population, was not associated with passive smoking (Hirayama, 1984). (druglibrary.net)
Chronic myelomon1
  • Specific skin lesions in chronic myelomonocytic leukemia: a spectrum of myelomonocytic and dendritic cell proliferations: a study of 42 cases. (medscape.com)
Mortality2
  • Conclusion Oral nutritional interventions are effective at increasing nutritional intake and improving some aspects of QOL in patients with cancer who are malnourished or are at nutritional risk but do not appear to improve mortality. (medscape.com)
  • In the first cohort study, the mortality of 91,540 nonsmoking wives in relation to the smoking habits of their husbands was investigated in Japan (Hirayama, 1984). (druglibrary.net)
Incidence3
  • A case/control study was made of the effect of parents' exposure to chemicals and other products on the incidence of leukemia in their children. (cdc.gov)
  • Although overall incidence is rare, leukemia is the most common type of childhood cancer. (nih.gov)
  • In another analysis of 1,474 patients with breast cancer who received adjuvant treatment with doxorubicin-containing regimens in clinical trials conducted at University of Texas M.D. Anderson Cancer Center, the incidence was estimated at 1.5% at 10 years. (nih.gov)
Childhood leukemia6
  • Childhood leukemia and parents' occupational and home exposures. (cdc.gov)
  • Most environmental risk factors have been found to be weakly and inconsistently associated with either form of acute childhood leukemia. (nih.gov)
  • Our review focuses on the demographics of childhood leukemia and the risk factors that have been associated with the development of childhood ALL or AML. (nih.gov)
  • Chronic myeloid leukemias make up most of the other childhood leukemia cases. (nih.gov)
  • 1987, 1988) reported elevated risks of childhood leukemia, which increased significantly with the number of days chloramphenicol was taken. (nih.gov)
  • While the support from individual studies is weak, the epidemiological studies demonstrate, for some methods of measuring exposure, a fairly consistent pattern of a small, increased risk with increasing exposure that is somewhat weaker for chronic lymphocytic leukemia than for childhood leukemia. (nih.gov)
Treated with rituximab2
  • B-cell leukemia can be treated with rituximab containing chemotherapy regimen. (medscape.com)
  • Progressive multifocal leukoencephalopathy in patients treated with rituximab: a 20-year review from the Southern Network on Adverse Reactions. (musc.edu)
Doxorubicin5
  • Doxorubicin is associated with a high rate of transient serum enzyme during therapy and to rare instances of clinically apparent acute liver injury with jaundice that can be severe and even fatal. (nih.gov)
  • Doxorubicin has potent activity in several forms of cancer, including acute leukemia, lymphomas, sarcomas and solid tumors. (nih.gov)
  • Long term folllow up studies of treated patients suggest that secondary malignancies may arise more frequently in those who receive high, total accumulative doses of doxorubicin. (nih.gov)
  • 13. A randomized comparative study of prednimustine and doxorubicin in patients with metastatic breast cancer. (nih.gov)
  • Patients in these studies received standard doses of doxorubicin and standard or escalated doses of cyclophosphamide (AC) adjuvant chemotherapy and were followed for 61,810 patient years. (nih.gov)
Adults2
  • The authors state that their results are consistent with those of animal studies which show that carcinogenic compounds are more likely to induce leukemia in mice exposed shortly after birth than in those exposed in-utero or as adults. (cdc.gov)
  • Cytarabine is an antineoplastic agent that is FDA approved for the treatment of acute non-lymphocytic leukemia of adults and children, acute lymphocytic leukemia and the blast phase of chronic myelocytic leukemia . (wikidoc.org)
Chemotherapy in patients2
  • Etoposide is administered as combination salvage chemotherapy in patients with relapsed AML. (medscape.com)
  • 4. Phase II trial of prednimustine as first-line chemotherapy in patients with advanced breast cancer. (nih.gov)
Secondary6
  • Scott AD, Lee M, Kubba F, Chu A. Acute generalized exanthematous pustulosis (AGEP) secondary to imatinib in a patient with chronic myeloid leukaemia. (medscape.com)
  • Clonal evolution revealed by whole genome sequencing in a case of primary myelofibrosis transformed to secondary acute myeloid leukemia. (medscape.com)
  • The occurrence of refractory secondary AML or MDS is more common when anthracyclines are given in combination with DNA-damaging anti-neoplastic agents or radiotherapy, when patients have been heavily pretreated with cytotoxic drugs, or when doses of anthracyclines have been escalated. (nih.gov)
  • The rate of developing secondary AML or MDS has been estimated in an analysis of 8,563 patients with early breast cancer treated in 6 studies conducted by the National Surgical Adjuvant Breast and Bowel Project (NSABP), including NSABP B-15. (nih.gov)
  • In both experiences, patients who received regimens with higher cyclophosphamide dosages, who received radiotherapy, or who were aged 50 or older had an increased risk of secondary AML or MDS. (nih.gov)
  • Pediatric patients are also at risk of developing secondary AML. (nih.gov)
19901
  • 1990). Three case reports have documented the occurrence of leukemia following chloramphenicol therapy in the absence of intervening aplastic anemia (IARC 1990). (nih.gov)
Adult3
  • 1996) found no association of chloramphenicol use with risk of adult leukemia. (nih.gov)
  • There is limited information regarding Off-Label Guideline-Supported Use of Cytarabine in adult patients. (wikidoc.org)
  • There is limited information regarding Off-Label Non-Guideline-Supported Use of Cytarabine in adult patients. (wikidoc.org)
Dosage1
  • Dosage should be reduced in patients with impaired hepatic function. (nih.gov)
Indications1
  • Current indications are limited to use in patients with breast cancer who have evidence of lymph node involvement after primary resection of the breast tumor. (nih.gov)
Exposure1
  • The NIEHS concludes that ELF-EMF exposure cannot be recognized at this time as entirely safe because of weak scientific evidence that exposure may pose a leukemia hazard. (nih.gov)
Elderly1
  • 19. Prednimustine in elderly patients with multiple myeloma: a phase II study. (nih.gov)
Breast cancer2
Type1
  • An extensive discussion of specific chemotherapeutic protocols can be found in Medscape Drugs & Diseases articles on the individual type of leukemia. (medscape.com)
Association1
Blood1
  • For patient education information, see Bruises and Blood Spots Under the Skin and Bleeding Disorders . (medscape.com)
Therapy3
  • For induction therapy patients should be treated in a facility with laboratory and supportive resources sufficient to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. (wikidoc.org)
  • Therapy should be started cautiously in patients with pre-existing drug-induced bone marrow suppression . (wikidoc.org)
  • Patients receiving this drug must be under close medical supervision and, during induction therapy, should have leukocyte and platelet counts performed daily. (wikidoc.org)
Growth1
  • Growth, as measured by new patient visits, increased by eleven percent year over year starting in fiscal year 2012, the year in which we set a goal to grow by fifty percent by 2017. (stanford.edu)
Agents3
  • These agents are indicated in patients receiving chemotherapy with signs of infection and neutropenia. (medscape.com)
  • 16. Clinical trial of prednimustine, Leo-1031 (NSC-134087), in patients with non-Hodgkin lymphomata and chronic lymphocytic leukaemia previously treated with steroids and alkylating agents. (nih.gov)
  • End of an era of administering erythropoiesis stimulating agents among Veterans Administration cancer patients with chemotherapy-induced anemia. (musc.edu)
Cancer patients2
  • [ 2 , 4 , 5 ] The data on weight loss in cancer patients show convincing associations with poorer clinical outcomes, but there is no evidence at present to suggest that there is a causal link between these variables. (medscape.com)
  • There are no universally accepted cut-offs for defining malnutrition, but there is broad acceptance that a low body mass index or substantial amounts of weight loss in the preceding months are indicative of malnutrition (6,9) and associated with poorer outcome in cancer patients (2,4). (medscape.com)
Support1
  • Methods Electronic searches of several databases including MEDLINE, EMBASE, and CINAHL (from the first record to February 2010) were searched to identify randomized controlled trials of patients with cancer who were malnourished or considered to be at risk of malnutrition and receiving oral nutritional support compared with routine care. (medscape.com)
Common1
  • The listing below includes some of the common chemotherapeutic drugs used to treat acute leukemia. (medscape.com)
Treatment2
  • Additionally, in patients with acquired factor X deficiency, treatment of the underlying cause may resolve the disorder. (medscape.com)
  • Intrathecal administration of cytarabine injection is indicated for the prophylaxis and treatment of meningeal leukemia . (wikidoc.org)
Evidence1
  • Background International guidelines on the nutritional management of patients with cancer recommend intervention with dietary advice and/or oral nutritional supplements in patients who are malnourished or those judged to be at nutritional risk, but the evidence base for these recommendations is lacking. (medscape.com)